Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Adenocarcinoma 1

Interventions

Fluorouracil 11Gemcitabine 8pembrolizumab 7Leucovorin 7Irinotecan 7Paclitaxel 6Oxaliplatin 5Carboplatin 5130-nm albumin-bound paclitaxel 5Nivolumab 4Cisplatin 4Albumin-Bound Paclitaxel 4Taxes 3Ramucirumab 3Radiosurgery 3Pemetrexed 3Docetaxel 3Capecitabine 3Bevacizumab 3vandetanib 2spartalizumab 2selinexor 2osimertinib 2folfirinox 2Radiation 2Cyclophosphamide 2zolbetuximab 1trastuzumab deruxtecan 1trametinib 1tofacitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Adenocarcinoma × polysaccharide-K × Clear all
NCT01685489 2015-10-27

A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer

Bastyr University

Phase 1 Withdrawn
Genitourinary

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡